Thc Biomed Intl Stock Performance
| THCBF Stock | USD 0 0.00 0.00% |
The entity owns a Beta (Systematic Risk) of 0.0, which indicates not very significant fluctuations relative to the market. the returns on MARKET and THC Biomed are completely uncorrelated.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days THC Biomed Intl has generated negative risk-adjusted returns adding no value to investors with long positions. Despite nearly stable fundamental drivers, THC Biomed is not utilizing all of its potentials. The current stock price disturbance, may contribute to mid-run losses for the stockholders. ...more
| Begin Period Cash Flow | 111.2 K | |
| Total Cashflows From Investing Activities | 2.5 M |
THC |
THC Biomed Relative Risk vs. Return Landscape
If you would invest 0.10 in THC Biomed Intl on November 9, 2025 and sell it today you would earn a total of 0.00 from holding THC Biomed Intl or generate 0.0% return on investment over 90 days. THC Biomed Intl is currently producing negative expected returns and takes up 0.0% volatility of returns over 90 trading days. Put another way, 0% of traded pink sheets are less volatile than THC, and 99% of all traded equity instruments are likely to generate higher returns over the next 90 trading days. Expected Return |
| Risk |
THC Biomed Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of THC Biomed for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for THC Biomed Intl can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| THC Biomed Intl generated a negative expected return over the last 90 days | |
| THC Biomed Intl has some characteristics of a very speculative penny stock | |
| THC Biomed Intl has accumulated 858.43 K in total debt with debt to equity ratio (D/E) of 0.56, which is about average as compared to similar companies. THC Biomed Intl has a current ratio of 0.91, indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due. Debt can assist THC Biomed until it has trouble settling it off, either with new capital or with free cash flow. So, THC Biomed's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like THC Biomed Intl sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for THC to invest in growth at high rates of return. When we think about THC Biomed's use of debt, we should always consider it together with cash and equity. | |
| The entity reported the revenue of 3.34 M. Net Loss for the year was (3.07 M) with loss before overhead, payroll, taxes, and interest of (1.03 M). | |
| THC Biomed Intl has accumulated about 1.16 M in cash with (1.86 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.01, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Roughly 29.0% of THC Biomed outstanding shares are owned by corporate insiders |
THC Biomed Fundamentals Growth
THC Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of THC Biomed, and THC Biomed fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on THC Pink Sheet performance.
| Return On Equity | -0.41 | |||
| Return On Asset | -0.15 | |||
| Profit Margin | (1.56) % | |||
| Operating Margin | (1.83) % | |||
| Current Valuation | 6.56 M | |||
| Shares Outstanding | 163.96 M | |||
| Price To Book | 0.73 X | |||
| Price To Sales | 1.37 X | |||
| Revenue | 3.34 M | |||
| EBITDA | (1.64 M) | |||
| Cash And Equivalents | 1.16 M | |||
| Cash Per Share | 0.01 X | |||
| Total Debt | 858.43 K | |||
| Debt To Equity | 0.56 % | |||
| Book Value Per Share | 0.04 X | |||
| Cash Flow From Operations | (1.86 M) | |||
| Earnings Per Share | (0.02) X | |||
| Total Asset | 14.75 M | |||
| Retained Earnings | (2.75 M) | |||
| Current Asset | 349 K | |||
| Current Liabilities | 648 K | |||
About THC Biomed Performance
By analyzing THC Biomed's fundamental ratios, stakeholders can gain valuable insights into THC Biomed's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if THC Biomed has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if THC Biomed has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
THC Biomed Intl Ltd. produces and sells medical and recreational cannabis in Canada. THC Biomed Intl Ltd. was founded in 2012 and is headquartered in Kelowna, Canada. Thc Biomed is traded on OTC Exchange in the United States.Things to note about THC Biomed Intl performance evaluation
Checking the ongoing alerts about THC Biomed for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for THC Biomed Intl help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| THC Biomed Intl generated a negative expected return over the last 90 days | |
| THC Biomed Intl has some characteristics of a very speculative penny stock | |
| THC Biomed Intl has accumulated 858.43 K in total debt with debt to equity ratio (D/E) of 0.56, which is about average as compared to similar companies. THC Biomed Intl has a current ratio of 0.91, indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due. Debt can assist THC Biomed until it has trouble settling it off, either with new capital or with free cash flow. So, THC Biomed's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like THC Biomed Intl sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for THC to invest in growth at high rates of return. When we think about THC Biomed's use of debt, we should always consider it together with cash and equity. | |
| The entity reported the revenue of 3.34 M. Net Loss for the year was (3.07 M) with loss before overhead, payroll, taxes, and interest of (1.03 M). | |
| THC Biomed Intl has accumulated about 1.16 M in cash with (1.86 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.01, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Roughly 29.0% of THC Biomed outstanding shares are owned by corporate insiders |
- Analyzing THC Biomed's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether THC Biomed's stock is overvalued or undervalued compared to its peers.
- Examining THC Biomed's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating THC Biomed's management team can have a significant impact on its success or failure. Reviewing the track record and experience of THC Biomed's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of THC Biomed's pink sheet. These opinions can provide insight into THC Biomed's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for THC Pink Sheet analysis
When running THC Biomed's price analysis, check to measure THC Biomed's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy THC Biomed is operating at the current time. Most of THC Biomed's value examination focuses on studying past and present price action to predict the probability of THC Biomed's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move THC Biomed's price. Additionally, you may evaluate how the addition of THC Biomed to your portfolios can decrease your overall portfolio volatility.
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas |